Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Inclusion Criteria: Subjects must meet all the following criteria to be eligible to participate in the study: * Signed informed consent * Diagnosis with histologically proven epithelioid unresectable MPM (stage I-IV) * Age ≥ 18 years at the time of signing informed consent * World Health Organization (WHO) performance status 0-1 * Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained at the time of screening: * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L (1500/μL) without granulocyte colony- stimulating factor support * Lymphocyte count ≥ 0.5 x 10\^9/L (500/μL) * Platelet count ≥ 100 x 10\^9/L (100,000/μL) without transfusion * Hemoglobin ≥ 90 g/L (9 g/dL) Patients may be transfused to meet this criterion * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions: * Patients with documented liver metastases: AST and ALT ≤ 5 x ULN * Patients with documented liver or bone metastases: ALP ≤ 5 x ULN * Total bilirubin ≤ 1.5 x ULN with the following exception: * Patients with known Gilbert disease: total bilirubin ≤ 3 x ULN * Creatinine ≤ 1.5 x ULN * Albumin ≥ 25 g/L (2.5 g/dL) * For patients not receiving therapeutic anticoagulation: prothrombin international normalized ration (PT-INR) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN * Negative Human Immunodeficiency Virus (HIV) test …